Kornimate/medical-research-clean huggingface dataset:
acute effects of static stretching duration on gastrocnemius muscle vascularization

Conditions: Muscle Stretching Exercises

Summary: stretching effects skeletal muscle flexibility, vascularity and physical performance. the aim of our study is to examine the acute effects of static stretching duration on gastrocnemius muscle vascularization in healthy participants by superb microvascular imaging (smi) and to compare the effects of 2 and 5 minutes of static stretching on blood flow.

the study will be included 30 healthy volunteers. the participants will be divided into two groups. static stretching was administered to the gastrocnemius muscle. stretching applications will be applied to the first group for 2 minutes and to the second group for 5 minutes. muscle vascularization will be evaluated by a new method, superb microvascular imaging (smi). smi is a recently developed ultrasound imaging technique that aims to visualize low velocity and small diameter blood vessel flow.

Eligibility criteria:
inclusion criteria: * healthy volunteers between the ages of 18-35, * without knee, hip, ankle and waist pathology, * has not undergone any surgery on the lower extremity. exclusion criteria: * rheumatic, musculoskeletal, neurological and vestibular problems, * bone pathologies, * joint laxity, * connective tissue disorders * diabetes, metabolic syndrome, arthritic or inflammatory problems

Keywords: gastrocnemius static stretching muscle vascularization superb microvascular imaging
evaluation of a diagnostic software for coronary artery disease using retrospective ccta data (codex-1 study)

Conditions: Coronary Artery Disease; Atherosclerosis; Myocardial Ischemia

Summary: the codex-1 study is a multicenter retrospective observational study designed to assess the diagnostic performance of a novel software application for coronary artery disease (cad) evaluation. the application integrates automated stenosis detection, ct-derived fractional flow reserve (ct-ffr), and plaque quantification, all performed on-site. a total of 1,000 patients who previously underwent coronary computed tomography angiography (ccta) and diagnostic invasive coronary angiography (ica) and/or other non-invasive imaging will be included. the study compares the diagnostic outputs of the software to current clinical practice and expert adjudication, focusing on cad-rads categorization, prediction of the need for percutaneous coronary intervention (pci), and reduction in unnecessary ica procedures.

coronary artery disease (cad) remains a leading cause of morbidity and mortality worldwide. coronary computed tomography angiography (ccta) has become a first-line diagnostic tool for patients with suspected cad, and its utility can be further enhanced through the use of advanced software for automated assessment. the codex-1 study is a multicenter, retrospective, observational cohort study aimed at evaluating the diagnostic performance of a novel on-site software application integrating three key features: automated stenosis detection and cad-rads categorization, ct-derived fractional flow reserve (ct-ffr), and quantitative plaque analysis. the study will include 1,000 patients who underwent ccta for cad assessment between 2019 and 2024 at four european centers. all participants also have comparator diagnostic data available, such as invasive coronary angiography (ica), stress mri, or ccta analyzed using alternative methods. the software's output will be compared against current clinical practice and expert consensus, with a focus on diagnostic accuracy, inter-reader variability, and the potential to reduce unnecessary ica procedures. the study will not involve any patient intervention, and all data analyses will be performed offline using de-identified imaging datasets. the results are expected to provide evidence on the feasibility and accuracy of integrating multiple diagnostic tools into a single application, enabling faster and more consistent cad diagnosis in clinical practice.

Eligibility criteria:
inclusion criteria: * age 18 years or older * underwent coronary computed tomography angiography (ccta) for the diagnosis or assessment of coronary artery disease (cad) between 2019 and 2024 * availability of comparator diagnostic data within 1 month before or after the ccta, such as: invasive coronary angiography (ica), stress mri, alternative ccta analysis software, documented clinical events exclusion criteria: - insufficient image quality to determine coronary stenosis or assess cad parameters in routine clinical use
a study of minirin melt in 24 months treatment in patients with nocturia

Conditions: Nocturia

Summary: a confirmation of the safety profile for minirin melt in clinical practice


Eligibility criteria:
inclusion criteria: * nocturia exclusion criteria: * habitual or psychogenic polydipsia, * known or suspected cardiac insufficiency * other conditions requiring treatment with diuretics * moderate and severe renal insufficiency * known hyponatremia * syndrome of inappropriate adh secretion
clinical characteristics of acutely hospitalized adults with acute pyelonephritis

Conditions: Acute Pyelonephritis

Summary: acute pyelonephritis is an acute infection. today the diagnosis is made primarily on the basis of unspecific clinical symptoms with flank tenderness combined with as a key clue. this study will investigate which clinical and paraclinical characteristics available within 4 hours of hospital stay, that describes the patients admitted in the emergency department with acute pyelonephritis the best.

acute pyelonephritis (apn) is a severe acute infection in the upper urinary tract, which quite frequently is seen in the emergency department (ed). in our study, we define apn as a urinary tract infection with extension above the bladder, implicated by systemic affection in a suspected urinary tract infection (ie, fever, chills, malaise and/or lethargy beyond normal, signs of sepsis). most often, an infection of the bladder ascends to the kidneys, causing apn. symptoms and clinical affection range from mild to severe, but it is always important to recognize and treat apn fast in order to prevent progression to sepsis, renal failure and ultimately death. the diagnosis apn is primarily made clinically based on symptoms and supported by elevated biomarkers such as c-reactive protein (crp) and leucocytes, and positive urinary test strips. the diagnostic process can be challenging as there is often weak and atypical symptoms. the classic symptoms indicating apn is flank tenderness, fever and nausea/vomiting. typical symptoms of cystitis (dysuria, pollakisuria, suprapubic pain, hematuria) are possible but often absent. especially elderly can present with more generalized signs of infection with nothing clearly indicating localization to the urinary tract. a positive urine culture verifies the diagnosis, but it is only available after a minimum of 24 hours. in this study, we seek to identify and quantify the patient characteristics available within 4 hours of hospital stay in patients with apn. the objectives are: * to identify clinical and paraclinical relevant information available within 4 hours of admission that are associated with apn patients * to investigate the association between adverse events and clinical and paraclinical relevant information in patients with apn.

Eligibility criteria:
inclusion criteria: * suspicion of apn assessed by the receiving physician. exclusion criteria: * if the attending physician considers that participation will delay a life-saving treatment or patient needs direct transfer to the intensive care unit. * admission within the last 14 days * verified covid-19 disease within 14 days before admission * pregnant women * severe immunodeficiencies: primary immunodeficiencies and secondary immunodeficiencies (hiv positive cd4 \ 20 mg/day prednisone or equivalent for \>14 days within the last 30 days), chemotherapy within 30 days)

Keywords: symptoms acute pyelonephritis clinical characteristics upper urinary tract infection emergency department
brain imaging and treatment studies of the night eating syndrome

Conditions: Night Eating Syndrome

Summary: the purpose of this study is to determine the effectiveness of the anti-depressant lexapro in the treatment of the night eating syndrome.

this proposal explores the implications of our two recent major discoveries: the striking efficacy of the selective serotonin reuptake inhibitor (ssri) sertraline in the control of the night eating syndrome (nes) and the unprecedented elevation in the level of serotonin transporter (sert) binding in the midbrain of persons with nes. our overall theory is that nes is associated with a syndrome-specific increase in sert derived from a genetic vulnerability which is affected by life stress. this increased sert activity produces a fall in post-synaptic serotonin levels. the investigators hypothesize that these decreased serotonin levels result in a significant phase delay in circadian food intake manifested by evening hyperphagia, nighttime ingestions and morning anorexia. ssris that block this increased sert activity increase synaptic serotonin levels and restore the circadian rhythm of food intake.

Eligibility criteria:
inclusion criteria: * men and women suffering from nes * ages 18 to 70 years * bmi greater than 18.5 kg/m2 exclusion criteria: * children or adolescents \<18 years * persons older than 70 * patients with diabetes mellitus * thyroid disease and other endocrine and metabolic disorders * use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics * current anorexia nervosa or bulimia nervosa * participation in an organized weight reduction program * use of antiobesity medication * an occupation that involves night shifts or other unusual time requirements -major depressive disorder (judged severe) * bipolar disorder * suicidal risk * current or past psychosis * substance use or abuse disorder within the past 6 months
invasive and non-invasive assessment of cerebral oxygenation in patients with severe traumatic brain injury (tbi)

Conditions: Brain Injuries

Summary: the purpose of this study is to investigate the relationship among regional transcranial oxygen saturation (rso2), brain tissue oxygen pressure (pbto2) and cerebral perfusion pressure (cpp) in patients with severe traumatic brain injury (tbi).

experience with rso2 assessed by near infrared spectroscopy (nirs) in patients with severe tbi is lacking. reports about the usefulness of rso2 are contradictory as regards its technical reliability and clinical value. continuous time-domain analysis comparing rso2, pbto2 and cpp has never been carried out and the correlation among these variables remains largely unknown. a significant association between rso2 and these clinically important variables would suggest that cerebral oximetry provides relevant data signifying that rso2 might be a useful tool assessing cerebral oxygenation in selected patients with tbi.

Eligibility criteria:
inclusion criteria: * severe traumatic brain injury (glasgow coma scale \< 9) * having an intraparenchymal cerebral icp/pbto2 catheter previously inserted. * expected length of icu stay \> 1 days exclusion criteria: * patient's relatives refusal to patient's inclusion in the study * patients necessitating ongoing resuscitation * end-stage in which death is imminent * deficient signal of rso2 impeding its proper valuation

Keywords: traumatic brain injury brain regional oxygen saturation (rso2) brain tissue oxygenation (pbto2) cerebral perfusion pressure (cpp)
efficacy and safety of xinyue capsule in the treatment of heart failure with preserved ejection fraction

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate the effect of xinyue capsule in the improvement cardiac function and reduction the level of heart failure biomarker nt-probnp in patients suffering from hf with an ejection fraction greater than or equal to 50%. researchers will also collect information on how much the heart disease has impact on patient's lives, and how well xinyue capsule treatment is tolerated. the study plans to enroll 246 male and female patients of the age of 18 years and above suffering from heart failure with ejection fraction greater than or equal to 50%. participants will take the study product as oral tablet with a dose 0.6 g tid daily. study duration will be up to 12 weeks.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years, and signed informed consent provided; 2. presence of symptoms such as dyspnea (including exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea), fatigue, poor appetite, and bilateral lower limb edema; 3. left ventricular ejection fraction (lvef) ≥ 50%, and meeting at least one of the following criteria: * nt-probnp ≥ 125 ng/l (sinus rhythm) or nt-probnp ≥ 365 ng/l (atrial fibrillation); exclusion criteria: 1. usage of xinyue capsule or other chinese patent medicines/herbal remedies aimed at alleviating heart failure symptoms or biomarkers within the past 90 days; 2. known intolerance or significant allergic reaction to xinyue capsule; 3. occurrence of cardiovascular adverse events within the past 90 days; 4. acute decompensated heart failure, life-threatening arrhythmias, acute myocardial infarction, or cardiogenic shock; 5. heart failure secondary to pulmonary hypertension, anemia, thyroid disorders, chronic obstructive pulmonary disease, or musculoskeletal disorders; 6. presence of cardiac amyloidosis, storage diseases (hemochromatosis, glycogen storage disease), severe valvular heart disease, severe infections, malignancies, or significant hepatic or renal insufficiency.

Keywords: heart failure with preserved ejection fraction
safety and efficacy of bexagliflozin compared to glimepiride as add-on therapy to metformin in type 2 diabetes subjects

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to investigate the effect of bexagliflozin compared to glimepiride as an add-on therapy to metformin in lowering hemoglobin a1c (hba1c) levels in subjects with type 2 diabetes mellitus (t2dm).

approximately 420 subjects with inadequately controlled t2dm on metformin will be recruited from north america and europe. subjects will be randomly assigned to receive bexagliflozin tablets, 20 mg, or glimepiride capsules, 2, 4 or 6 mg, in a ratio of 1:1 once daily for 96 weeks. subjects will continue to take metformin for the duration of the study.

Eligibility criteria:
inclusion criteria: * diagnosis of t2dm * currently taking metformin or taking metformin and one additional oral medication for diabetes * body mass index (bmi) ≤ 45 kg/m2 * stable dose of blood pressure or cholesterol medications (if applicable) for at least 30 days exclusion criteria: * hypersensitivity or other contraindication to the safe use of sulfonylurea or glimepiride * diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young * current use of injected therapy for treatment of diabetes (insulin or glp-1 receptor agonist therapy) or thiazolidinedione class drugs * history of genitourinary tract infections * evidence of abnormal liver function * myocardial infarction, stroke or hospitalization for heart failure within 3 months of screening * prior kidney transplant or evidence of kidney problems * pregnant or nursing
effect of high flow nasal during exercise in copd patients

Conditions: COPD Exacerbation

Summary: early pulmonary rehabilitation is recommended after an episode of severe exacerbation of chronic obstructive pulmonary disease (copd). however, its implementation is challenging particularly as regard exercise training. high flow ventilation in reducing work of breathing and dyspnea may improve exercise tolerance. the aim of this study is to carry out the acute effect of high flow nasal cannula on exercise endurance in post-exacerbation copd patients


Eligibility criteria:
inclusion criteria: * a diagnosis of copd exclusion criteria: * exercise contraindication any musculoskeletal problems, cardiovascular or neurological comorbidities that limits exercise. * ph \< 7,35 * body temperature \> 38°c * cardiac frequency \> 100 bpm at rest * systolic blood pressure \< 100 mmhg * exacerbation during the study

Keywords: copd exercise high flow nasal muscle oxygenation pulmonary rehabilitation
tall stature women fetal weight estimation

Conditions: Ultrasonography, Prenatal

Summary: to investigate the difference of clinical vs sonographic fetal weight estimation of tall women stature (above 10t percentile)

women undergoing delivery after week 39 will be estimated of their fetal wight with clinical estimation and then sonographic estimation. each women will be case control 1:1 for the actual fetal weight of the delivery. the fetal weight will be blinded for each estimation. primary outcome is the actual fetal weight secondary outcomes will be mode of delivery, fetal complication as apgar score and fetal hypoxia and maternal complication as perineal laceration

Eligibility criteria:
inclusion criteria: * pregnant women above 172 cm height * above 39 weeks of gestation exclusion criteria: * contraindication for vaginal delivery * intrauterus growth restriction

Keywords: clinical weight estimation
maternal serum homocysteine levels and uterine artery pulsatility indices in preterm labor

Conditions: Preterm Labor

Summary: study included all pregnant women admitted with threatened preterm labor during the study period. all participants underwent estimation of maternal serum homocysteine level and assessment of uterine artery doppler indices.

prospective cohort study. study approval by local ethics committee. informed written consent. study included all pregnant women admitted with threatened preterm labor during the study period. all participants underwent estimation of maternal serum homocysteine level and assessment of uterine artery doppler indices.

Eligibility criteria:
inclusion criteria: * singleton pregnancy * more than 28 and less than 35 gestational weeks. * threatened preterm labor exclusion criteria: * medical disorders complicating pregnancy * obstetric conditions complicating pregnancy (e.g., placenta previa, multiple gestation,pprom, ....etc) * fetal anomalies or distress
dppe in combination with epirubicin and cyclophosphamide in the treatment of breast cancer

Conditions: Breast Cancer; Metastases

Summary: the purpose of this trial is to study dppe combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to anthracycline treatment. stratification allocation will be within the following subgroups: 1. prior cytotoxic treatment; 2. estrogen receptor status; 3. ecog performance status; 4. number of cycles of chemotherapy.

endpoints of the trial are as follows: primary: overall survival; secondary: response rate, progression free survival, toxicity, neurocognitive function.

Eligibility criteria:
inclusion criteria: * histological proof of breast cancer * documented evidence of metastatic and/or recurrent breast cancer * presence of at least one bi-dimensional or uni-dimensional lesion * ecog status 0, 1 or 2 * quality of life

Keywords: metastatic breast cancer
reference nurse program for pressure ulcers in primary care

Conditions: Pressure Ulcers

Summary: introduction: pressure ulcers (pu) are the most common chronic wounds in all levels of care in health centers. the chronic wound care by skilled personnel is key to healing and management of these injuries. an inter-clinical telematic program for pu in primary care (pc) can improve the effectiveness of interventions and cost savings. objective: to evaluate the effectiveness and costs reduction after the implementation in pc setting of a chronic wounds reference nurse and a teleconsultation program aimed to nurses for the management of pu in patients in home care setting. methodology: a prospective pilot clinical trial in which 46 primary care nurses in osakidetza will be randomly assigned to two parallel groups: experimental group and control group. each nurse will recruit at least 1 new patient in home care with pu in stage ii-iii. the intervention will consist of a telematic advice from the reference nurse regarding chronic wound management in relation to a specific pu. patients will be monitored for 8 weeks with a minimum of 4 repeated measurements of the resvech index 2.0. to evaluate the effectiveness of the intervention, multilevel models or linear mixed models to take into account the auto-correlation at the individual level and nurse, will be used


Eligibility criteria:
inclusion criteria: * new cases of pu in stage ii-iii, treated by the same nurse over time at patient's home. (stage ii: partial loss of skin thickness that affects the epidermis, dermis, or both. ulcer surface that looks like abrasion, blister, or shallow crater; stage iii: full thickness loss of skin involving damage or necrosis of subcutaneous tissue that may extend down to but not through the underlying fascia) exclusion criteria: * patients with chronic wounds that are not pu * pu in patients with plastic surgery * patients who move periodically * patients requiring hospitalization during follow-up * patients in which nurse is expected to be changed during follow-up * terminal patients
study comparing postoperative treatment after surgical decompression for lumbar spinal stenosis.

Conditions: Spinal Stenosis

Summary: the aim of the study is to assess the benefit of wearing a lumbar orthosis after surgery for spinal stenosis. it will be evaluated if a post-surgery immobilization for 6 weeks with a lumbar orthosis reduces early recurrence, increases walking distance, decreases significantly faster pain and pain medication after surgery

spinal stenosis and orthoses the study situation in this regard is very poor, high-quality level 1 studies are not available. a study by prateepavanich et al. from 2001 shows advantages in the therapy with lumbar orthoses in neurogenic spinal claudication in the context of conservative therapy (9). regarding postoperative prescription, expert opinions have long diverged (10). nevertheless, in a survey of north american spine surgeons, over 60% reported prescribing an orthosis postoperatively (11). 2 aim of the study the aim of this study is to show that patients after surgical decompression for lumbar spinal stenosis and patients after surgical sequestrectomy benefit from temporary postoperative immobilization using a lumbar orthosis. to show that postoperative therapy with a lumbar orthosis prolongs walking distance and reduces early recurrence. it will be shown that postoperative pain decreases significantly faster and thus pain medication can be reduced faster early postoperatively.

Eligibility criteria:
inclusion criteria: * decompression with hemi-/ partial laminectomy, one. laminectomy, and foraminotomy. flavectomy with undercutting due to uni-and multi-segmental spinal stenosis. * age 20-80 years * pre-operative walking distance at least 100m * consent form signed by the patient exclusion criteria: * fusion surgery or recurrent surgery * tumors of the spine * cervical spinal stenosis or myelopathy * rheumatoid arthritis or similar autoimmune disease * infection - request for a pension * dyspnea due to heart failure with limited walking distance * peripheral arterial occlusive disease (paod)-
pharmacokinetics of drugs administered to children

Conditions: Pediatric ALL

Summary: this is a prospective study of children \<21 years of age with the goal of characterizing the pk of drugs administered per standard of care as prescribed by the treating caregiver.


Eligibility criteria:
inclusion criteria: * children (\< 21 years of age) who are receiving understudied drugs of interest per standard of care as prescribed by their treating caregiver exclusion criteria: * failure to obtain consent/assent (as indicated)

Keywords: pharmacokinetics